Literature DB >> 22009766

Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assay.

Valsamo K Anagnostou1, Anastasios T Dimou, Taxiarchis Botsis, Elizabeth J Killiam, Mark D Gustavson, Robert J Homer, Daniel Boffa, Vassiliki Zolota, Dimitrios Dougenis, Lynn Tanoue, Scott N Gettinger, Frank C Detterbeck, Konstantinos N Syrigos, Gerold Bepler, David L Rimm.   

Abstract

BACKGROUND: The importance of definitive histological subclassification has increased as drug trials have shown benefit associated with histology in nonsmall-cell lung cancer (NSCLC). The acuity of this problem is further exacerbated by the use of minimally invasive cytology samples. Here we describe the development and validation of a 4-protein classifier that differentiates primary lung adenocarcinomas (AC) from squamous cell carcinomas (SCC).
METHODS: Quantitative immunofluorescence (AQUA) was employed to measure proteins differentially expressed between AC and SCC followed by logistic regression analysis. An objective 4-protein classifier was generated to define likelihood of AC in a training set of 343 patients followed by validation in 2 independent cohorts (n = 197 and n = 235). The assay was then tested on 11 cytology specimens.
RESULTS: Statistical modeling selected thyroid transcription factor 1 (TTF1), CK5, CK13, and epidermal growth factor receptor (EGFR) to generate a weighted classifier and to identify the optimal cutpoint for differentiating AC from SCC. Using the pathologist's final diagnosis as the criterion standard, the molecular test showed a sensitivity of 96% and specificity of 93%. Blinded analysis of the validation sets yielded sensitivity and specificity of 96% and 97%, respectively. Our assay classified the cytology specimens with a specificity of 100% and sensitivity of 87.5%.
CONCLUSIONS: Molecular classification of NSCLC using an objective quantitative test can be highly accurate and could be translated into a diagnostic platform for broad clinical application.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22009766     DOI: 10.1002/cncr.26450

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Down-regulation of LATS2 in non-small cell lung cancer promoted the growth and motility of cancer cells.

Authors:  Feng Yao; Hongcheng Liu; Zhigang Li; Chenxi Zhong; Wentao Fang
Journal:  Tumour Biol       Date:  2014-11-13

2.  Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization.

Authors:  Jason A Hanna; Hallie Wimberly; Salil Kumar; Frank Slack; Seema Agarwal; David L Rimm
Journal:  Biotechniques       Date:  2012-04       Impact factor: 1.993

3.  Optimized Protocol for Quantitative Multiple Reaction Monitoring-Based Proteomic Analysis of Formalin-Fixed, Paraffin-Embedded Tissues.

Authors:  Jacob J Kennedy; Jeffrey R Whiteaker; Regine M Schoenherr; Ping Yan; Kimberly Allison; Melissa Shipley; Melissa Lerch; Andrew N Hoofnagle; Geoffrey Stuart Baird; Amanda G Paulovich
Journal:  J Proteome Res       Date:  2016-07-27       Impact factor: 4.466

4.  Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1).

Authors:  Vamsidhar Velcheti; David L Rimm; Kurt A Schalper
Journal:  J Thorac Oncol       Date:  2013-06       Impact factor: 15.609

Review 5.  Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis.

Authors:  Yue Yu; Jie He
Journal:  Front Med       Date:  2013-05-17       Impact factor: 4.592

6.  Classification of lung cancer tumors based on structural and physicochemical properties of proteins by bioinformatics models.

Authors:  Faezeh Hosseinzadeh; Mansour Ebrahimi; Bahram Goliaei; Narges Shamabadi
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

7.  Prediction of lung tumor types based on protein attributes by machine learning algorithms.

Authors:  Faezeh Hosseinzadeh; Amir Hossein Kayvanjoo; Mansuor Ebrahimi; Bahram Goliaei
Journal:  Springerplus       Date:  2013-05-24

8.  Aberrant Mucin5B expression in lung adenocarcinomas detected by iTRAQ labeling quantitative proteomics and immunohistochemistry.

Authors:  Yan Li; Xiangchun Wang; Minghui Ao; Edward Gabrielson; Frederic Askin; Hui Zhang; Qing Kay Li
Journal:  Clin Proteomics       Date:  2013-11-01       Impact factor: 3.988

9.  Predicting survival time of lung cancer patients using radiomic analysis.

Authors:  Ahmad Chaddad; Christian Desrosiers; Matthew Toews; Bassam Abdulkarim
Journal:  Oncotarget       Date:  2017-11-01

10.  Novel image markers for non-small cell lung cancer classification and survival prediction.

Authors:  Hongyuan Wang; Fuyong Xing; Hai Su; Arnold Stromberg; Lin Yang
Journal:  BMC Bioinformatics       Date:  2014-09-19       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.